Published in Br J Cancer on October 20, 2003
The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention. Nat Rev Cancer (2012) 2.06
Differentiation therapy of leukemia: 3 decades of development. Blood (2009) 2.02
PPAR gamma signaling exacerbates mammary gland tumor development. Genes Dev (2004) 1.58
Liposarcoma: molecular genetics and therapeutics. Sarcoma (2010) 1.55
A developmental model of sarcomagenesis defines a differentiation-based classification for liposarcomas. Am J Pathol (2008) 1.43
Rosiglitazone and risk of cancer: a meta-analysis of randomized clinical trials. Diabetes Care (2008) 1.33
An experimental model for the study of well-differentiated and dedifferentiated liposarcoma; deregulation of targetable tyrosine kinase receptors. Lab Invest (2010) 1.19
PPARγ agonists enhance ET-743-induced adipogenic differentiation in a transgenic mouse model of myxoid round cell liposarcoma. J Clin Invest (2012) 1.16
The prince and the pauper. A tale of anticancer targeted agents. Mol Cancer (2008) 1.12
Regression of drug-resistant lung cancer by the combination of rosiglitazone and carboplatin. Clin Cancer Res (2008) 1.09
Solid tumor differentiation therapy - is it possible? Oncotarget (2012) 1.05
Advances in the targeted therapy of liposarcoma. Onco Targets Ther (2015) 0.99
Systems biology: a therapeutic target for tumor therapy. Cancer Microenviron (2008) 0.97
Pioglitazone induces a proadipogenic antitumor response in mice with PAX8-PPARgamma fusion protein thyroid carcinoma. Endocrinology (2011) 0.97
The synthetic triterpenoid CDDO-Im inhibits fatty acid synthase expression and has antiproliferative and proapoptotic effects in human liposarcoma cells. Cancer Invest (2008) 0.96
Peroxisome proliferator-activated receptors and cancer: challenges and opportunities. Br J Pharmacol (2011) 0.95
Retroperitoneal liposarcoma: current insights in diagnosis and treatment. Front Surg (2015) 0.95
Antineoplastic effects of rosiglitazone and PPARgamma transactivation in neuroblastoma cells. Br J Cancer (2006) 0.94
Activating peroxisome proliferator-activated receptor gamma mutant promotes tumor growth in vivo by enhancing angiogenesis. Cancer Res (2009) 0.93
Liposarcoma in a colonic polyp: case report and review of the literature. Dig Dis Sci (2007) 0.92
Chondrosarcoma and peroxisome proliferator-activated receptor. PPAR Res (2008) 0.89
PPARgamma Ligand as a Promising Candidate for Colorectal Cancer Chemoprevention: A Pilot Study. PPAR Res (2010) 0.88
Novel systemic therapies in advanced liposarcoma: a review of recent clinical trial results. Cancers (Basel) (2013) 0.87
Kinome profiling of myxoid liposarcoma reveals NF-kappaB-pathway kinase activity and casein kinase II inhibition as a potential treatment option. Mol Cancer (2010) 0.86
Pleomorphic liposarcoma: clinical observations and molecular variables. Cancer (2011) 0.85
Chemotherapy and chemoprevention by thiazolidinediones. Biomed Res Int (2015) 0.85
Clinical Use of PPARgamma Ligands in Cancer. PPAR Res (2008) 0.84
PPAR Ligands for Cancer Chemoprevention. PPAR Res (2008) 0.83
PPARs: Interference with Warburg' Effect and Clinical Anticancer Trials. PPAR Res (2012) 0.83
To Live or to Die: Prosurvival Activity of PPARgamma in Cancers. PPAR Res (2008) 0.83
Troglitazone, a peroxisome proliferator-activated receptor gamma ligand, induces growth inhibition and apoptosis of HepG2 human liver cancer cells. World J Gastroenterol (2008) 0.82
In vivo effects of rosiglitazone in a human neuroblastoma xenograft. Br J Cancer (2010) 0.82
The Role of PPARs in the Endothelium: Implications for Cancer Therapy. PPAR Res (2008) 0.81
A Ligand for peroxisome proliferator-activated receptor gamma inhibits human cholangiocarcinoma cell growth: potential molecular targeting strategy for cholangioma. Dig Dis Sci (2006) 0.81
PPARgamma and Agonists against Cancer: Rational Design of Complementation Treatments. PPAR Res (2008) 0.78
Differential effects of PPARgamma activation by the oral antidiabetic agent pioglitazone in Barrett's carcinoma in vitro and in vivo. J Gastroenterol (2009) 0.77
Current classification, treatment options, and new perspectives in the management of adipocytic sarcomas. Onco Targets Ther (2016) 0.76
Notch activation drives adipocyte dedifferentiation and tumorigenic transformation in mice. J Exp Med (2016) 0.76
Clinical relevance of peroxisome proliferator-activated receptor-gamma expression in myxoid liposarcoma. BMC Cancer (2016) 0.75
Commonalities in the Association between PPARG and Vitamin D Related with Obesity and Carcinogenesis. PPAR Res (2016) 0.75
PPARgamma: The Portrait of a Target Ally to Cancer Chemopreventive Agents. PPAR Res (2008) 0.75
Integrative Genomic Analyses Yield Cell-Cycle Regulatory Programs with Prognostic Value. Mol Cancer Res (2016) 0.75
Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell (1994) 17.58
An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem (1995) 13.34
mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. Genes Dev (1994) 10.44
Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma. Nature (1993) 5.69
PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected]. Science (2000) 3.87
Liposarcoma: new entities and evolving concepts. Ann Diagn Pathol (2000) 3.34
Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor. Proc Natl Acad Sci U S A (1997) 3.22
PPAR gamma 2 regulates adipose expression of the phosphoenolpyruvate carboxykinase gene. Mol Cell Biol (1995) 3.14
Prognostic impact of P53 status, TLS-CHOP fusion transcript structure, and histological grade in myxoid liposarcoma: a molecular and clinicopathologic study of 82 cases. Clin Cancer Res (2001) 2.80
Loss-of-function mutations in PPAR gamma associated with human colon cancer. Mol Cell (1999) 2.71
Medical significance of peroxisome proliferator-activated receptors. Lancet (1999) 2.50
Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci U S A (1999) 2.45
PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J Clin Invest (2002) 2.31
Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor gamma and mediated by inhibition of translation initiation. Cancer Res (2001) 1.96
Translocation t(12;16)(q13;p11) in myxoid liposarcoma and round cell liposarcoma: molecular and cytogenetic analysis. Cancer Res (1995) 1.91
A phase II study of troglitazone, an activator of the PPARgamma receptor, in patients with chemotherapy-resistant metastatic colorectal cancer. Cancer J (2002) 1.33
Cytogenetic and molecular genetic analyses of liposarcoma and its soft tissue simulators: recognition of new variants and differential diagnosis. Virchows Arch (2001) 1.30
Mutational analysis of the peroxisome proliferator-activated receptor gamma gene in human malignancies. Cancer Res (2001) 1.25
Apoptosis induced by activation of peroxisome-proliferator activated receptor-gamma is associated with Bcl-2 and NF-kappaB in human colon cancer. Life Sci (2002) 1.19
Rosiglitazone. Int J Clin Pract (2000) 0.85
Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet (2001) 6.11
Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. Ann Oncol (2005) 5.27
Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat Genet (2001) 4.66
Malignant angiomyolipoma of the liver: a hitherto unreported variant. Histopathology (2000) 3.24
Cytogenetic evidence of clonality in cutaneous benign fibrous histiocytomas: a report of the CHAMP study group. Histopathology (2000) 3.05
The der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25. Oncogene (2001) 2.97
18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer (2003) 2.97
Coordinated expression and amplification of the MDM2, CDK4, and HMGI-C genes in atypical lipomatous tumours. J Pathol (2000) 2.56
Correlation between clinicopathological features and karyotype in lipomatous tumors. A report of 178 cases from the Chromosomes and Morphology (CHAMP) Collaborative Study Group. Am J Pathol (1996) 2.42
Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol (2005) 2.39
Prominent axonopathy in the brain and spinal cord of transgenic mice overexpressing four-repeat human tau protein. Am J Pathol (1999) 2.12
MRI findings in acute cerebellitis. Eur Radiol (2004) 2.12
Cell kinetic measurements in prostate cancer. Int J Radiat Oncol Biol Phys (1997) 1.83
Cytogenetic and fluorescence in situ hybridization investigation of ring chromosomes characterizing a specific pathologic subgroup of adipose tissue tumors. Cancer Genet Cytogenet (1993) 1.77
Resistance of young gelatinase B-deficient mice to experimental autoimmune encephalomyelitis and necrotizing tail lesions. J Clin Invest (1999) 1.64
Elevated risk for MPNST in NF1 microdeletion patients. Am J Hum Genet (2003) 1.62
Trisomies 8 and 20 in desmoid tumors. Cancer Genet Cytogenet (1996) 1.61
The development of the intrahepatic bile ducts in man: a keratin-immunohistochemical study. Hepatology (1988) 1.59
Arsenic and non-cirrhotic portal hypertension. A report of eight cases. J Hepatol (1990) 1.59
Combined morphologic and karyotypic study of 59 atypical lipomatous tumors. Evaluation of their relationship and differential diagnosis with other adipose tissue tumors (a report of the CHAMP Study Group). Am J Surg Pathol (1996) 1.48
Prominent cerebral amyloid angiopathy in transgenic mice overexpressing the london mutant of human APP in neurons. Am J Pathol (2000) 1.42
Complex tumor-specific t(X;18) in seven synovial sarcoma tumors. Cancer Genet Cytogenet (2009) 1.41
PLAG1 fusion oncogenes in lipoblastoma. Cancer Res (2000) 1.35
Uneven hepatic iron and phosphorus distribution in beta-thalassemia. J Hepatol (1995) 1.33
Synovial sarcoma of the larynx and hypopharynx. Ann Otol Rhinol Laryngol (1998) 1.31
Intrahepatic bile duct development in the rat: a cytokeratin-immunohistochemical study. Lab Invest (1988) 1.27
Cytokeratin expression in hepatocellular carcinoma: an immunohistochemical study. Hum Pathol (1988) 1.23
A cytokeratin immunohistochemical study of cholestatic liver disease: evidence that hepatocytes can express 'bile duct-type' cytokeratins. Histopathology (1989) 1.23
Prognostic value of KIT/PDGFRA mutations in gastrointestinal stromal tumours (GIST): Polish Clinical GIST Registry experience. Ann Oncol (2011) 1.22
Aneurysmal bone cyst of the nose with 17p13 involvement. Virchows Arch (2001) 1.21
Keratin immunohistochemistry in normal human liver. Cytokeratin pattern of hepatocytes, bile ducts and acinar gradient. Virchows Arch A Pathol Anat Histopathol (1987) 1.21
FDG-PET for preoperative staging of bladder cancer. Eur J Nucl Med Mol Imaging (2005) 1.20
Angiomyxolipoma shares cytogenetic changes with lipoma, spindle cell/pleomorphic lipoma and myxoma. Virchows Arch (2001) 1.19
Correlation between clinicopathological features and karyotype in spindle cell sarcomas. A report of 130 cases from the CHAMP study group. Am J Pathol (1999) 1.19
Cytogenetic characterization of peripheral nerve sheath tumours: a report of the CHAMP study group. J Pathol (2000) 1.18
MicroRNA-206 expression levels correlate with clinical behaviour of rhabdomyosarcomas. Br J Cancer (2010) 1.16
Extraorbital inflammatory pseudotumor of the head and neck: CT and MR findings in three patients. AJNR Am J Neuroradiol (1999) 1.16
Pelvic floor descent in females: comparative study of colpocystodefecography and dynamic fast MR imaging. J Magn Reson Imaging (1999) 1.15
Additional evidence of a variant translocation t(12;22) with EWS/CHOP fusion in myxoid liposarcoma: clinicopathological features. J Pathol (1997) 1.15
High frequency of beta-catenin heterozygous mutations in extra-abdominal fibromatosis: a potential molecular tool for disease management. Br J Cancer (2010) 1.14
Is calcifying fibrous pseudotumor a late sclerosing stage of inflammatory myofibroblastic tumor? Am J Surg Pathol (1999) 1.14
Cytogenetic analysis of 46 pleomorphic soft tissue sarcomas and correlation with morphologic and clinical features: a report of the CHAMP Study Group. Chromosomes and MorPhology. Genes Chromosomes Cancer (1998) 1.14
The depolarization sequence of the human heart surface computed from measured body surface potentials. IEEE Trans Biomed Eng (1988) 1.14
Xanthogranulomatous pyelonephritis with emphasis on computerized tomography scan. Retrospective study of 20 cases and literature review. Urology (1987) 1.13
The NPM-ALK and the ATIC-ALK fusion genes can be detected in non-neoplastic cells. Am J Pathol (2001) 1.13
Partial nephrectomy for renal cell carcinoma can achieve long-term tumor control. J Urol (1998) 1.13
Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability. Br J Cancer (2008) 1.13
MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma. Eur J Cancer (2008) 1.12
Renal pseudotumor due to a retained perirenal sponge: CT features. J Comput Assist Tomogr (1992) 1.12
Prominent axonopathy and disruption of axonal transport in transgenic mice expressing human apolipoprotein E4 in neurons of brain and spinal cord. Am J Pathol (2000) 1.11
Cytogenetic, clinical, and morphologic correlations in 78 cases of fibromatosis: a report from the CHAMP Study Group. CHromosomes And Morphology. Mod Pathol (2000) 1.08
The contribution of magnetic resonance imaging to the three-dimensional treatment planning of localized prostate cancer. Int J Radiat Oncol Biol Phys (1999) 1.08
Changing phenotype of gastrointestinal stromal tumours under imatinib mesylate treatment: a potential diagnostic pitfall. Histopathology (2005) 1.07
Diffusion-weighted MR imaging in the evaluation of renal infection: preliminary results. JBR-BTR (2002) 1.07
Diffusion-weighted MRI in sporadic Creutzfeldt-Jakob disease. Neurology (1999) 1.06
Clinical impact of molecular and cytogenetic findings in synovial sarcoma. Genes Chromosomes Cancer (2001) 1.06
Vascular endothelial growth factor counteracts the loss of phospho-Akt preceding motor neurone degeneration in amyotrophic lateral sclerosis. Neuropathol Appl Neurobiol (2007) 1.05
Clear cell sarcoma of the stomach. Histopathology (2002) 1.05
[Lipoma and atypical lipomatous tumor within the same neoplasia: Evidence for a continuous transition]. Pathologe (2010) 1.04
Detection of the SYT-SSX fusion transcripts in formaldehyde-fixed, paraffin-embedded tissue: a reverse transcription polymerase chain reaction amplification assay useful in the diagnosis of synovial sarcoma. Mod Pathol (1998) 1.04
Expression of MHC products by normal and abnormal bile duct epithelium. J Hepatol (1986) 1.04
Cellular angiofibroma: another mesenchymal tumour with 13q14 involvement, suggesting a link with spindle cell lipoma and (extra)-mammary myofibroblastoma. Histopathology (2007) 1.04
Various regions within the alpha-helical domain of the COL1A1 gene are fused to the second exon of the PDGFB gene in dermatofibrosarcomas and giant-cell fibroblastomas. Genes Chromosomes Cancer (1998) 1.03
Combined morphologic and karyotypic study of 28 myxoid liposarcomas. Implications for a revised morphologic typing, (a report from the CHAMP Group). Am J Surg Pathol (1996) 1.02
1q gain and CDT2 overexpression underlie an aggressive and highly proliferative form of Ewing sarcoma. Oncogene (2011) 1.02
Molecular cytogenetic mapping of recurrent chromosomal breakpoints in tenosynovial giant cell tumors. Virchows Arch (2002) 1.02
Lesions of 13q may occur independently of deletion of 16q in spindle cell/pleomorphic lipomas. Histopathology (1997) 1.01
Myofibroblastoma of the breast: genetic link with spindle cell lipoma. J Pathol (2000) 1.01
Expression of the novel extracellular matrix component tenascin in normal and diseased human liver. An immunohistochemical study. J Hepatol (1990) 1.01
Hyaline vascular Castleman's disease with HMGIC rearrangement in follicular dendritic cells: molecular evidence of mesenchymal tumorigenesis. Am J Surg Pathol (2002) 1.00
Mutation analysis of P73 and TP53 in Merkel cell carcinoma. Br J Cancer (2000) 1.00
Accuracy of combined computerized tomography and fine needle aspiration cytology in lymph node staging of localized prostatic carcinoma. J Urol (1994) 0.99
Focal xanthogranulomatous pyelonephritis mimicking a renal tumor: CT- and MR-findings and evolution under therapy. Nephrol Dial Transplant (1997) 0.99
Expression of HMGI-C and HMGI(Y) in ordinary lipoma and atypical lipomatous tumors: immunohistochemical reactivity correlates with karyotypic alterations. Am J Pathol (1997) 0.99
Trisomy 7 and trisomy 8 in dividing and non-dividing tumor cells in Dupuytren's disease. Cancer Genet Cytogenet (1999) 0.99
Invasion and MMP expression profile in desmoid tumours. Br J Cancer (2004) 0.98
Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases. Leukemia (2012) 0.98
MiR-17-92 and miR-221/222 cluster members target KIT and ETV1 in human gastrointestinal stromal tumours. Br J Cancer (2013) 0.98
Motor unit potential contribution to surface electromyography. Acta Physiol Scand (1997) 0.97
N-Acetyltransferase expression and DNA binding of N-hydroxyheterocyclic amines in human prostate epithelium. Carcinogenesis (1999) 0.97
Multifocal epithelioid angiosarcoma of the small intestine. Virchows Arch (2000) 0.97
Real-time reverse transcription-PCR and fluorescence in-situ hybridization are complementary to understand the mechanisms involved in HER-2/neu overexpression in human breast carcinomas. Histopathology (2005) 0.96
Uneven hepatic copper distribution in Wilson's disease. J Hepatol (1995) 0.96
Cyclophosphamide versus ifosfamide: preliminary report of a randomized phase II trial in adult soft tissue sarcomas. Cancer Chemother Pharmacol (1986) 0.96
Chromosome 9 alterations and trisomy 22 in central chondrosarcoma: a cytogenetic and DNA flow cytometric analysis of chondrosarcoma subtypes. Diagn Mol Pathol (2001) 0.96
HLA expression in human hepatocellular carcinoma. Br J Cancer (1988) 0.95